Donor lymphocyte infusion after allogeneic stem cell transplantation

被引：55

作者：

Castagna, Luca ^{[1
]}

Sarina, Barbara ^{[1
]}

Bramanti, Stefania ^{[1
]}

Perseghin, Paolo ^{[2
]}

Mariotti, Jacopo ^{[1
]}

Morabito, Lucio ^{[1
]}

机构：

[1] Ist Clin Humanitas, Programma Trapianto Humanitas Canc Ctr, I-20800 Rozzano, Italy

[2] Osped San Gerardo, Apheresis Unit, ASST Monza, Monza, MB, Italy

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2016年 / 54卷 / 03期

关键词：

DLI; Allogeneic transplantation; Relapse; Pre-emeptive; Hematological disease; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; RELAPSED HEMATOLOGIC MALIGNANCIES; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; LONG-TERM REMISSIONS; LOW-DOSE AZACITIDINE; HIGH RESPONSE RATE;

D O I：

10.1016/j.transci.2016.05.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use. (C) 2016 Published by Elsevier Ltd.

引用

页码：345 / 355

页数：11

共 90 条

[1] Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].

Alvarez, I ;

Sureda, A ;

Caballero, MD ;

Urbano-Ispizzua, A ;

Ribera, JM ;

Canales, M ;

García-Conde, J ;

Sanz, G ;

Arranz, R ;

Bernal, MT ;

de la Serna, J ;

Díez, JL ;

Moraleda, JM ;

Rubió-Félix, D ;

Xicoy, B ;

Martínez, C ;

Mateos, MV ;

Sierra, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183

[2] T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect [J].

Alyea, E ;

Weller, E ;

Schlossman, R ;

Canning, C ;

Webb, I ;

Doss, D ;

Mauch, P ;

Marcus, K ;

Fisher, D ;

Freeman, A ;

Parikh, B ;

Gribben, J ;

Soiffer, R ;

Ritz, J ;

Anderson, K .

BLOOD, 2001, 98 (04) :934-939

[3] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[4] Hematopoietic-cell transplantation at 50 [J].

Appelbaum, Frederick R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) :1472-1475

[5] Understanding anti-leukemia responses to donor lymphocyte infusion [J].

Bachireddy, Pavan ;

Wu, Catherine J. .

ONCOIMMUNOLOGY, 2014, 3 (03)

[6] Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion [J].

Bachireddy, Pavan ;

Hainz, Ursula ;

Rooney, Michael ;

Pozdnyakova, Olga ;

Aldridge, Julie ;

Zhang, Wandi ;

Liao, Xiaoyun ;

Hodi, F. Stephen ;

O'Connell, Karyn ;

Haining, W. Nicholas ;

Goldstein, Natalie R. ;

Canning, Christine M. ;

Soiffer, Robert J. ;

Ritz, Jerome ;

Hacohen, Nir ;

Alyea, Edwin P., III ;

Kim, Haesook T. ;

Wu, Catherine J. .

BLOOD, 2014, 123 (09) :1412-1421

[7]

Bacigalupo A, 2004, HAEMATOLOGICA, V89, P1238

[8] High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].

Badros, A ;

Barlogie, B ;

Morris, C ;

Desikan, R ;

Martin, SR ;

Munshi, N ;

Zangari, M ;

Toor, A ;

Cottler-Fox, M ;

Fassas, A ;

Aniassie, E ;

Schichman, S ;

Tricot, G .

BLOOD, 2001, 97 (09) :2574-2579

[9]

BAR BMAM, 1993, J CLIN ONCOL, V11, P513

[10] T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect [J].

Barrett, AJ ;

Mavroudis, D ;

Tisdale, J ;

Molldrem, J ;

Clave, E ;

Dunbar, C ;

Cottler-Fox, M ;

Phang, S ;

Carter, C ;

Okunnieff, P ;

Young, NS ;

Read, EJ .

BONE MARROW TRANSPLANTATION, 1998, 21 (06) :543-551

← 1 2 3 4 5 6 7 8 9 →